These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 34013341)

  • 1. Serum potassium changes due to concomitant ACEI/ARB and spironolactone therapy: A systematic review and meta-analysis.
    Villa-Zapata L; Carhart BS; Horn JR; Hansten PD; Subbian V; Gephart S; Tan M; Romero A; Malone DC
    Am J Health Syst Pharm; 2021 Dec; 78(24):2245-2255. PubMed ID: 34013341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Bolignano D; Palmer SC; Navaneethan SD; Strippoli GF
    Cochrane Database Syst Rev; 2014 Apr; (4):CD007004. PubMed ID: 24782282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease.
    An J; Niu F; Sim JJ
    Pharmacotherapy; 2021 Dec; 41(12):998-1008. PubMed ID: 34655484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of SGLT2i and RAASi and Their Combination on Risk of Hyperkalemia in DKD: A Network Meta-Analysis.
    Luo X; Xu J; Zhou S; Xue C; Chen Z; Mao Z
    Clin J Am Soc Nephrol; 2023 Aug; 18(8):1019-1030. PubMed ID: 37256921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments.
    Hirai T; Yamaga R; Fujita A; Itoh T
    J Clin Pharm Ther; 2018 Dec; 43(6):829-835. PubMed ID: 29908131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
    Han SW; Won YW; Yi JH; Kim HJ
    Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
    J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of adding Rheum officinale to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal function in patients with chronic renal failure: A meta-analysis of randomized controlled trials
.
    Yang Y; Ma YP; Zhang Z; Dai PL; Li P; Li WG
    Clin Nephrol; 2018 Jun; 89(6):445-454. PubMed ID: 29208203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in diabetic nephropathy: a systematic review and meta-analysis.
    Du YH; Guan CJ; Li LY; Gan P
    Ann Palliat Med; 2022 Mar; 11(3):1093-1101. PubMed ID: 35365039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Renin-Angiotensin System Blockers Increases Serum Potassium in Anuric Hemodialysis Patients.
    Movilli E; Camerini C; Gaggia P; Zubani R; Cancarini G
    Am J Nephrol; 2018; 48(2):79-86. PubMed ID: 30071530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined use of renin-angiotensin-aldosterone system-acting agents: a cross-sectional study.
    Farcas A; Leucuta D; Bucsa C; Mogosan C; Dumitrascu D
    Int J Clin Pharm; 2016 Dec; 38(6):1390-1397. PubMed ID: 27677980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children.
    Vaz de Castro PAS; Bitencourt L; Pereira BWS; Lima AQR; Hermida HS; Moreira Neto CR; Mestriner MD; Simões E Silva AC
    Pediatr Nephrol; 2022 Mar; 37(3):499-508. PubMed ID: 34686915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker therapy for IgA nephropathy: A meta-analysis of randomized controlled trials.
    Ji Y; Yang K; Xiao B; Lin J; Zhao Q; Bhuva MS; Yang H
    J Cell Biochem; 2019 Mar; 120(3):3689-3695. PubMed ID: 30270542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin II Receptor Blockers and Cancer Risk: A Meta-Analysis of Randomized Controlled Trials.
    Zhao YT; Li PY; Zhang JQ; Wang L; Yi Z
    Medicine (Baltimore); 2016 May; 95(18):e3600. PubMed ID: 27149494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with COVID-19: a systematic review and meta-analysis.
    Lo KB; Bhargav R; Salacup G; Pelayo J; Albano J; McCullough PA; Rangaswami J
    Expert Rev Cardiovasc Ther; 2020 Dec; 18(12):919-930. PubMed ID: 32945216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adequate intake of potassium does not cause hyperkalemia in hypertensive individuals taking medications that antagonize the renin angiotensin aldosterone system.
    Malta D; Arcand J; Ravindran A; Floras V; Allard JP; Newton GE
    Am J Clin Nutr; 2016 Oct; 104(4):990-994. PubMed ID: 27581475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
    Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
    Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short- and long-term outcomes with renin-angiotensin-aldosterone inhibitors in renal transplant recipients: A meta-analysis of randomized controlled trials.
    Liao RX; Lyu XF; Tang WJ; Gao K
    Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28186357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF
    Cochrane Database Syst Rev; 2009 Jul; (3):CD007004. PubMed ID: 19588415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of combination therapy with sodium-glucose cotransporter 2 inhibitors and renin-angiotensin system blockers in patients with type 2 diabetes: a systematic review and meta-analysis.
    Tian B; Deng Y; Cai Y; Han M; Xu G
    Nephrol Dial Transplant; 2022 Mar; 37(4):720-729. PubMed ID: 33605424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.